TruScreen offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and wellbeing of women around the world.
TruScreen’s world-class technology has the power to save lives
TruScreen is a cost-effective test that can be used outside existing laboratory infrastructure and has high potential to aid in reducing cervical cancer mortality. This new technology detects pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The system uses low levels of electricity and light to examine the cervix as a hand-held wand is gently moved over the surface of the cervix.
Unlike the Pap test, tissue samples are not collected, which minimises discomfort for patients. TruScreen has been extensively evaluated in studies involving more than 10,000 women worldwide, and it has been proven as, or more, effective than top quality conventional Pap tests.